Summary
- Altimmune has joined the coronavirus vaccine race and is looking for a partner to get the vaccine into human trials by August. As a result, the stock surged over 100%.
- I believe the company's nasal vaccine technology would deliver a best-in-class vaccine for a pandemic event.
- I still see ALT to be undervalued with a current market cap around $55M. A COVID-19 partnership deal should deliver a payment that is greater than its market cap.
- I discuss my plans for my ALT position following the press release, while we wait for an update on a partnership.
Altimmune (NASDAQ:ALT) recently publicized that they have been working on "a novel single-dose, intranasal vaccine using Altimmune's proprietary technology to protect against COVID-19, the disease caused by the SARS-CoV-2 virus." In my previous ALT article, I discussed why I was disappointed that the company was not partaking in the COVID-19 race despite having a superior platform technology for pandemic events. Admittedly, I was happy the company had decided to stay on the sidelines due to other companies having a head start and the cost of developing a new vaccine. Now, the world is starting to experience the pandemic, and regulatory agencies appear to be looking for multiple solutions to the crisis. In addition, the company is looking for a partner to help develop and hopefully commercialize their vaccine. As a result, ALT's share price has rocketed up and has joined the COVID-19 ticker hype. I believe the increase in attention from the market will force the Street to recognize Altimmune's impressive platform technology and pipeline programs.
I plan to provide some background on how the company's nasal vaccine technology could be the best-in-class for pandemic viruses and discuss the key aspects of the company's recent press release. Moreover, I will present my views on the potential program and why their decision to jump into the race could lead to bigger opportunities. Finally, I take a look at the company's current valuation and how I plan to manage my ALT position following the COVID-19 press release.
Contagion Platform
Altimmune's RespirVec technology is a fascinating means to defend against pandemic threats. RespirVec vaccines employ a specially designed adenovirus that triggers a unique immune response that is not seen in present-day injectable vaccines. Above all, RespirVec technology is capable of activating an immune response equivalent to an authentic infection, consequently producing concurrent humoral and cell-mediated immunity. Furthermore, RespirVec is an intranasal technology which removes the need for injection while also activating the mucosal immune system. The company's influenza vaccine, NasoVAX, demonstrated impressive pre-clinical data that elicited complete protection from a deadly strain of flu only days after administration.

Figure 1: NasoVAX Attributes (Source: ALT)
Furthermore, RespirVec vaccines could be quickly manufactured due to the company commissioning the PER.C6 cell line of recombinant adenoviral "rAd" vectors. rAd vectored vaccines elicit a 'self-adjuvanting' accomplishment by activating innate immunity. Furthermore, studies have recognized that intranasal rAd vectored vaccines have no systemic adverse events in humans. Additionally, rAd constructed single-dose intranasal rAd vectored influenza vaccines have the potential to protect against hazardous influenza viruses in humans. Perhaps, the most intriguing aspect is that rAd vectored nasal influenza vaccines trigger a grander antigen-specific IgA and IgG responses in the respiratory tract, which is a common route of infection. What is more, the data supports that a RespirVec vaccine could produce a virus-specific activated T-cells in the lung that is superior to intramuscularly injected rAd vaccines.
Considering the points above, Altimmune has the technology to develop a first-class COVID-19 vaccine that would allow for a stronger immunization response, efficient administration, rapid and inexpensive manufacturing, and is suitable for mass vaccination maneuvers.

